Honoured to have new role in RSM
I am very excited and honoured to have been appointed President Elect of the Oncology Section of the Royal Society of Medicine.
This is one of the most senior positions in oncology in the UK and I am thrilled to be holding such a prestigious role.
As President Elect, I will work towards being President of the Oncology Section for the years 2020 to 2022.
With so many exciting developments taking place in cancer research, I cannot think of a more interesting time to be at the heart of helping to ensure everyone is informed of latest advances.
The RSM is one of the major providers of postgraduate medical education in the UK with over 400 academic and public events every year.
At the Royal Marsden Hospital, where I work, we have been very pleased this year to begin treating patients with the UK’s first MRLinac machine following a multi-million grant from the Medical Research Council (MRC).
The state-of-the-art machine combines two technologies for the first time – an MRI scanner to precisely locate the tumour site and a linear accelerator that accurately delivers doses of radiation even to moving tumours.
Advances in treatment and care
Other advances in treatment include proton beam therapy, gene therapy and immunotherapy, which stimulates the body’s immune system to attack cancer cells. Immunotherapy in particular is showing very promising results in saving patients from having to undergo extreme chemotherapy.
New approaches to the care of cancer patients are also being trialled including the development of multi-disciplinary teams specialising in specific organ sites. Other improvements include greater supportive care to patients and their families, and increased public awareness of clinical trials, vital for research.
As a clinical researcher, I am aware of the challenges of recruiting patients to trials and one of my goals will be to stimulate a discussion about how the profession can make this process easier for all.
Contact me for further information.